Selected publications
- Reduced-dose ipilimumab with standard-dose pembrolizumab: is less more?. The Lancet. Oncology. 2017 In Process GET IT
- Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy. Ophthalmology. 2017 In Process GET IT
- Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer Treatment Reviews. 2017 Academic Article GET IT
- Health-related quality of life results from the phase III CheckMate 067 study. European journal of cancer (Oxford, England : 1990). 2017 Academic Article GET IT
- T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017 Academic Article GET IT
- Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab. Journal of the National Cancer Institute. 2017 Academic Article GET IT
- Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment. EBioMedicine. 2017 In Process GET IT
- Elevated Blood Neutrophil-to-Lymphocyte Ratio: A Readily Available Biomarker Associated with Death due to Disease in High Risk Nonmetastatic Melanoma. Annals of Surgical Oncology. 2017 In Process GET IT
- Patient perspectives on ipilimumab across the melanoma treatment trajectory. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2017 In Process GET IT
- Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. European journal of cancer (Oxford, England : 1990). 2017 Academic Article GET IT
- Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Academic Article GET IT
- Better use of immune checkpoint inhibition: Treating higher risk patients and examining neurologic toxicity. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 In Process GET IT
- Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma. Melanoma Research. 2017 In Process GET IT
- Reaffirming and Clarifying the American Society of Clinical Oncology's Policy Statement on the Critical Role of Phase I Trials in Cancer Research and Treatment. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 In Process GET IT
- Response after treatment with pembrolizumab in a patient with myelophthisis due to melanoma: the role of checkpoint inhibition in the bone. Journal for ImmunoTherapy of Cancer. 2017 In Process GET IT
- Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. Journal for ImmunoTherapy of Cancer. 2017 In Process GET IT
- Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors. The British journal of dermatology. 2016 In Process GET IT
-
The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2016
In Process
GET IT
Times cited: 1 - Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 In Process GET IT
-
Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.
Cancer.
2016
Academic Article
GET IT
Times cited: 8 - Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. Journal of translational medicine. 2016 In Process GET IT
- The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer. 2016 Academic Article GET IT
- An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 In Process GET IT
-
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
The Lancet. Oncology.
2016
Academic Article
GET IT
Times cited: 42 - Melanoma central nervous system metastases: current approaches, challenges, and opportunities. Pigment Cell and Melanoma Research. 2016 In Process GET IT
- Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 In Process GET IT
- Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents. The oncologist. 2016 In Process GET IT
- Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. JAMA oncology. 2016 Information Resource GET IT
- Localized sinonasal mucosal melanoma: Outcomes and associations with stage, radiotherapy, and positron emission tomography response. Head & neck. 2016 In Process GET IT
- Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. European journal of cancer (Oxford, England : 1990). 2016 Academic Article GET IT
- Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis. The oncologist. 2016 In Process GET IT
-
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.
Annals of oncology : official journal of the European Society for Medical Oncology.
2016
In Process
GET IT
Times cited: 4 - Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 In Process GET IT
- A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma. Melanoma Research. 2016 In Process GET IT
- Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. European journal of cancer (Oxford, England : 1990). 2016 Academic Article GET IT
- Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. Immunotherapy. 2016 Academic Article GET IT
- Irradiation and immunotherapy: From concept to the clinic. Cancer. 2016 Information Resource GET IT
- Targeting T Cell Co-receptors for Cancer Therapy. Immunity. 2016 Academic Article GET IT
- Reply to N. Lowy et al and to J. Dhanda et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 In Process GET IT
- Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. Cancer immunology research. 2016 Academic Article GET IT
-
Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition.
Current oncology reports.
2016
Information Resource
GET IT
Times cited: 4 - Checkpoint Blockade for the Treatment of Advanced Melanoma. Cancer treatment and research. 2016 Information Resource GET IT
- Editorial. Clinical Skin Cancer. 2016 Editorial Article GET IT
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Information Resource GET IT
-
Improving the Evidence Base for Treating Older Adults With Cancer: American Society of Clinical Oncology Statement.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2015
Academic Article
GET IT
Times cited: 31 - Safety of Infusing Ipilimumab Over 30 Minutes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
- Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. Nature. 2015 Academic Article GET IT
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
- Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center. British journal of haematology. 2015 Academic Article GET IT
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. The New England journal of medicine. 2015 Academic Article GET IT
- Immune Checkpoint Blockade in Cancer Therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Information Resource GET IT
- Immune checkpoint modulation: rational design of combination strategies. Pharmacology & therapeutics. 2015 Information Resource GET IT
- Liver resection and ablation for metastatic melanoma: A single center experience. Journal of Surgical Oncology. 2015 Academic Article GET IT
-
Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment.
International journal of radiation oncology, biology, physics.
2015
Academic Article
GET IT
Times cited: 59 - Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. The New England journal of medicine. 2015 Academic Article GET IT
- On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Science translational medicine. 2015 Information Resource GET IT
-
Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.
Cell research.
2015
Article
GET IT
Times cited: 22 -
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.
Cell research.
2015
Academic Article
GET IT
Times cited: 17 -
Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy.
American journal of clinical oncology.
2015
Information Resource
GET IT
Times cited: 28 -
American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2015
Academic Article
GET IT
Times cited: 13 - Managing immune checkpoint-blocking antibody side effects. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting. 2015 Information Resource GET IT
- Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma. Cancers. 2015 Academic Article GET IT
- Genetic basis for clinical response to CTLA-4 blockade in melanoma. The New England journal of medicine. 2014 Academic Article GET IT
-
CTLA-4 antibodies: new directions, new combinations.
ONCOLOGY.
2014
Information Resource
GET IT
Times cited: 10 -
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.
Lancet.
2014
Academic Article
GET IT
Times cited: 608 - Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes. Cancer immunology research. 2014 Academic Article GET IT
-
Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes.
International journal of radiation oncology, biology, physics.
2014
Information Resource
GET IT
Times cited: 57 - Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocrine-Related Cancer. 2014 Information Resource GET IT
-
Checkpoint blocking antibodies in cancer immunotherapy.
FEBS Letters.
2014
Information Resource
GET IT
Times cited: 92 -
Current options and future directions in the systemic treatment of metastatic melanoma.
Journal of Community and Supportive Oncology.
2014
Academic Article
GET IT
Times cited: 1 -
Immune modulation in cancer with antibodies.
Annual review of medicine.
2014
Information Resource
GET IT
Times cited: 146 - Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Cancers. 2014 Information Resource GET IT
- Ipilimumab in patients with melanoma and autoimmune disease. Cancers. 2014 Academic Article GET IT
-
Markers for anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy in melanoma.
Methods in molecular biology (Clifton, N.J.).
2014
Academic Article
GET IT
Times cited: 3 - Opportunistic infections in patients treated with immunotherapy for cancer. Cancers. 2014 Academic Article GET IT
-
Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.
Cancer.
2013
Article
GET IT
Times cited: 59 -
Checkpoint modulation in melanoma: an update on ipilimumab and future directions.
Current oncology reports.
2013
Information Resource
GET IT
Times cited: 12 - Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer immunology research. 2013 Information Resource GET IT
-
Nivolumab plus ipilimumab in advanced melanoma.
The New England journal of medicine.
2013
Academic Article
GET IT
Times cited: 1533 -
Ipilimumab for patients with advanced mucosal melanoma.
The oncologist.
2013
Academic Article
GET IT
Times cited: 46 - Immunomodulatory therapy for melanoma: ipilimumab and beyond. Clinics in Dermatology. 2013 Information Resource GET IT
- Mucosal melanoma: pathogenesis, clinical behavior, and management. Current oncology reports. 2012 Information Resource GET IT
- A man with Klinefelter's syndrome and new abdominal distension: a discussion of evaluation and management. Journal of gastrointestinal cancer. 2012 Academic Article GET IT
- Causes and consequences of microRNA dysregulation. Cancer journal (Sudbury, Mass.). 2012 Information Resource GET IT
- Abscopal effect in a patient with melanoma. The New England journal of medicine. 2012 Information Resource GET IT
-
Therapeutic implications of KIT in melanoma.
Cancer journal (Sudbury, Mass.).
2012
Information Resource
GET IT
Times cited: 19 - Immunologic correlates of the abscopal effect in a patient with melanoma. The New England journal of medicine. 2012 Academic Article GET IT
-
Chemotherapy in the Rwandan countryside: universal issues a world away.
Annals of internal medicine.
2012
Academic Article
GET IT
Times cited: 1 - Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy. Cancer journal (Sudbury, Mass.). 2011 Information Resource GET IT
- A piece of my mind. The ice cream man. JAMA. 2011 Academic Article GET IT
- Radiotherapy and Immune Checkpoint Blockade for Melanoma: A Promising Combinatorial Strategy in Need of Further Investigation. Cancer journal (Sudbury, Mass.). Academic Article GET IT